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Towards a structural understanding of Friedreich’s ataxia: the
solution structure of frataxin
Giovanna Musco1, Gunter Stier2, Bernhard Kolmerer2†, Salvatore Adinolfi1,
Stephen Martin1, Tom Frenkiel1, Toby Gibson2 and Annalisa Pastore1*
Background: Lesions in the gene for frataxin, a nuclear-encoded mitochondrial
protein, cause the recessively inherited condition Friedreich’s ataxia. It is
thought that the condition arises from disregulation of mitochondrial iron
homeostasis, with concomitant oxidative damage leading to neuronal death.
Very little is, as yet, known about the biochemical function of frataxin. 
Results: Here, we show that the mature form of recombinant frataxin behaves in
solution as a monodisperse species that is composed of a 15-residue-long
unstructured N terminus and an evolutionarily conserved C-terminal region that
is able to fold independently. The structure of the C-terminal domain consists of
a stable seven-stranded antiparallel β sheet packing against a pair of parallel
helices. The structure is compact with neither grooves nor cavities, features that
are typical of iron-binding modules. Exposed evolutionarily conserved residues
cover a broad area and all cluster on the β-sheet face of the structure,
suggesting that this is a functionally important surface. The effect of two
clinically occurring mutations on the fold was checked experimentally. When the
mature protein was titrated with iron, no tendency to iron-binding or to
aggregation was observed.
Conclusions: Knowledge of the frataxin structure provides important guidelines
as to the nature of the frataxin binding partner. The absence of all the features
expected for an iron-binding activity, the large conserved area on its surface
and lack of evidence for iron-binding activity strongly support an indirect
involvement of frataxin in iron metabolism. The effects of point mutations
associated with Friedreich’s ataxia can be rationalised by knowledge of the
structure and suggest possible models for the occurrence of the disease in
compound heterozygous patients. 
Introduction
In recent years a new mechanism of genetic disease has
been revealed in which repeats of DNA trinucleotide
sequences become amplified in the germline, with conse-
quent anomalies in gene expression. To date, more than 12
human genetic diseases have been associated with the
expansion of CAG, CGG and GAA repeats. The diseases
can be grouped into two classes according to whether or
not the triplet repeats occur in coding or in noncoding
regions (see [1] and references therein). In the first class,
which includes Huntington’s disease, the spinocerebellar
ataxias and spinobulbar muscular atrophy, expanded CAG
repeats encode a polyglutamine segment within an open-
reading frame of an expressed sequence. The poly-Gln
repeats behave as ‘gain-of-function’ mutations and the
associated diseases, characterised by progressive neuronal
loss, are dominantly inherited. In the second class, which
includes fragile X syndrome and myotonic dystrophy, the
triplet expansion occurs either in the untranslated regions
(UTRs) or in introns. These inherited diseases present a
multisystem pathology. The most recent addition to this
second group is Friedreich’s ataxia (FRDA; OMIM code
229300; http://www3.ncbi.nlm.gov/omim) (for reviews see
[2]), which is the most common form of hereditary ataxia,
affecting 1 out of 50,000 individuals [3,4]. FRDA is a
neurodegenerative disorder in which neurons with very
long axons die back from the periphery. It usually mani-
fests itself by early adolescence and progresses to severe
physical disability, often complicated by hypertrophic
cardiomyopathy leading to premature death. The disorder
is generally characterized by one or more of the following:
an unsteady gait; dysarthria; muscular weakness of the legs;
lower limb areflexia; diabetes mellitus; carbohydrate intol-
erance [5]. It is now well established that FRDA is a genet-
ically homogenous recessive entity, of which the locus has
been mapped to chromosome 9 [6,7]. The gene encodes a
novel small protein of 210 amino acids called frataxin [8].
About 94% of FRDA patients are homozygous for an
intronic GAA repeat expansion in the frataxin gene [9].
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The number of repeats ranges from 8–22 in normal indi-
viduals and from 120–1700 in affected patients [8].
Homozygous FRDA patients have undetectable or
extremely low levels of frataxin mRNA [8], which sug-
gests that the disease is caused by deficiency of frataxin
protein. In a few cases, FRDA patients are heterozygous
for an expanded repeat in one allele and a deleterious
point mutation in the other. Missense, nonsense and splic-
ing point mutations have all been found. 
The biochemical function of frataxin is unknown. Frataxin
is ubiquitously (though not abundantly) expressed, reach-
ing the highest concentration in the heart, spinal cord and
dorsal root ganglia [10], all tissues that are heavily depen-
dent on oxidative respiration. The expression levels corre-
late well with the pattern of neuronal degeneration,
cardiomyopathy and increased risk of diabetes observed in
the disease. No sequence homology is detected with pro-
teins of known function. However, mitochondrial localiza-
tion of frataxin was predicted by the finding of
homologues (designated cyaY) in purple bacteria, the
closest relatives of the mitochondrial genome, suggesting
that chronic peroxidative damage is the cause of neuronal
death [11]. A mitochondrial location was rapidly demon-
strated experimentally in yeast and human cells
[10,12–15]. The yeast studies also showed that frataxin
mutants are highly sensitive to oxidants and readily accu-
mulate lethal quantities of iron in the mitochondria. 
The evidence that frataxin is closely involved in iron
homeostasis has steadily increased. Some years ago, unique
iron deposits were reported in cardiac myocytes [16,17].
Mitochondrial iron is significantly higher in fibroblasts from
patients with FRDA than in fibroblasts from control
patients [18,19]. Additional evidence from the yeast system
that implicates mitochondrial dysfunction in FRDA
includes the observation that deletion of the yeast frataxin
gene (YFH1) results in a decrease of respiration, a deple-
tion of mitochondrial DNA, oxidative stress and an increase
in mitochondrial iron concentration [10,12–15,20,21]. Col-
lectively these results have led to the view that frataxin has
a role in controlling mitochondrial iron homeostasis and
that FRDA is caused by oxidative damage. Consistent with
this view, some success in alleviating clinical progression of
FRDA has been reported recently; combined treatment
with the antioxidants N-acetylcysteine, selenium and
vitamin E led to a decrease in the rate of clinical decline in
an FRDA patient [22]. Treatment with the lipid-soluble
antioxidant idebenone (a coenzyme Q analogue) resulted
in a dramatic decrease in myocardial hypertrophy [23].
These preliminary findings could be consistent with either
a direct or an indirect involvement of frataxin in iron utilisa-
tion. Recently, it has been reported that the yeast homo-
logue of frataxin shows a ferritin-like behaviour in vitro: in
the presence of an iron excess, the protein has been
reported to form large aggregates able to segregate iron
from solution [24]. Several potential ligands besides iron
have been envisaged for frataxin, ranging from vitamin E to
mitochondrial DNA (mtDNA) to another protein [11].
Experiments searching for proteic partners have so far
identified only the mitochondrial-processing peptidase
MPP-β, a protein that is responsible for cleavage of the
frataxin mitochondrial targeting sequence [25–27]. 
Some help in providing a clue to function might come from
the increasing number of clinically relevant frataxin
mutants and their correlation with phenotype [9]. The pos-
sibility of distinguishing residues that are essential for the
stability of the three-dimensional fold from those that are
directly implicated in the function might help to shed light
onto the cellular role of frataxin. Mapping loss-of-function
mutations to functional positions would provide useful
tools for testing candidate ligands of frataxin. Knowledge of
the tertiary structure is essential to reveal these positions. 
Our project aims at the structural and functional character-
ization of frataxin. In the following sections, we describe
the structure determination of frataxin in solution. We
show that the evolutionary conserved C terminus is neces-
sary and sufficient for forming an independently folded
domain. The structure allows us to compare it with other
iron-binding proteins and to rationalize the role of each of
the clinically observed point mutations. The effect on the
structure of two mutations was checked experimentally. 
Results
Frataxin is a monomer and contains two structurally
distinct regions
Two distinct regions can be identified in the frataxin
sequences: a non-conserved N-terminal region, absent
from the bacterial cyaY proteins, and a strongly conserved
C-terminal block (Figure 1). The N terminus includes the
mitochondrial import sequence, which is cleaved off the
mature frataxin protein spanning residues 75–210. The
sequence present in the mature protein has characteristics
of a globular domain with a predicted α–β structure [11].
No classical iron-binding motifs (e.g., conserved cysteines)
are identifiable in its sequence. Two constructs of human
frataxin were prepared: one construct (hereafter referred
to as L_Fra) spanned residues 63–210 of the human
protein and a shorter one (hereafter referred to as S_Fra)
contained the conserved C-terminal domain (amino acids
90–210) — at the time the project was started, the mature
form was not known. Interestingly, the longer construct
was degraded naturally and quantitatively during purifica-
tion to a fragment spanning residues 75–210, which corre-
sponds to the mature form of the protein [26].
Characterization of L_Fra carried out by analytical gel fil-
tration showed that recombinant frataxin behaves as a
monodisperse species (data not shown). According to cir-
cular dichromism (CD) and nuclear magnetic resonance
(NMR) spectroscopies, both constructs are folded, but the
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additional residues in L_Fra do not contribute to thermo-
dynamic stability as demonstrated by comparable values
of the melting points of the two constructs (62°C). This
observation strongly suggests that the additional residues
are unfolded. Furthermore the heteronuclear single
quantum correlation (HSQC) NMR spectra of the two
constructs are superimposable (Figure 2) with the implica-
tion that the N terminus does not alter the folded struc-
ture. As these N-terminal residues provide no significant
information about the tertiary fold, we decided to concen-
trate our attention on the S_Fra construct for the purpose
of structure determination. The long construct L_Fra,
which corresponds to the mature frataxin, was used for the
binding assays and for production of the mutants. 
Frataxin is an α–β protein
Structure determination of S_Fra was carried out using
NMR. Complete spectral assignment was achieved as
described by Musco et al. [28]. Typical NOE effects, such
as the secondary chemical shift pattern and 3JHNHA scalar
coupling constants, together with amide hydrogen–deu-
terium exchange experiments indicate that frataxin has an
α–β fold (Figure 3). The structure consists of two helical
regions (residues 95–113 and 182–194), that flank an
antiparallel β sheet, which is formed by six consecutive
strands, designated β1 to β6 spanning residues 122–127,
131–136, 142–147, 154–159, 162–169 and 172–175. The
presence of a seventh short strand between residues 179
and 181 is suggested by typical β-sheet connectivities,
even though it is not supported by the secondary chemical
shifts. The overall topology is α1β1β2β3β4β5β6β7α2. 
Relevant parameters that define the quality of the calcu-
lated structures are reported in Table 1. Figure 4a shows a
bundle of the 15 lowest energy structures. Apart from the
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Figure 1
Alignment of currently known frataxin and cyaY
sequences, displayed with Clustal X colours to
emphasise conserved sequence features [46].
The white-on-black L indicates the N terminus
of mature frataxin. Point mutations causing
Friedreich’s ataxia (Table 2) are listed in the
line FA_Mutations. The 2D_structure line
summarises the content of secondary structure
in terms of ‘A’ helical and ‘B’ strand residues.
N termini are incomplete for At, Ce and Sp
frataxins. See the Materials and methods
section for species identifiers.
At_Frataxin ..mrgeen
Sc_Frataxin mikrslaslvrvs------------------svmgrrymiaaagg-erarfcpavtnkknh
Sp_Frataxin ..mqslraafrrrtpifl
Ce_Frataxin 
Mm_Frataxin mwafggraavgllp-rtasrasawvgnprwrepivtcgrrglhvtvnagat-rhahlnlh-ylq
Hs_Frataxin mwtlgrravagllaspspaqaqtltrvprpaelaplcgrrglrtdidatctprrassnqrglnq
Frataxin_No. 1.......10........20........30........40........50........60....
    Ec_CyaY mndsefhrladqlwltieerlddwdg----dsdidceinggvltitfen-
    Yp_CyaY mndsefhqladqlmlyieetldsftg----dsdidyetnggvmtltfen-
   Ech_CyaY mndsefhqladtlmlkveetldqfdg----dadidyetnggvmtlsfen-
    Hi_CyaY mniaefhqnieqvwqkieeelenqg------advdcetqgsvftitfdn-
    Rp_CyaY mnntafsklaettivyivdkieeqdl----egiidvdlqgdilnldten-
At_Frataxin ssshtndkslenhtgfskpehgkyvnreeefhklanftinhllekiedygdn-vqidgfdidygnevltlklgs-
Sc_Frataxin tvntfqkrfvesstdgqvvpqevlnlplekyheeaddyldhlldsleelsea-hpdcipdvelshgvmtleipa-
Sp_Frataxin kpyefstnvfglrcryysqvrhngaltdleyhrvaddtldvlndtfedllee-vgkkdydiqyangvitlmlge-
Ce_Frataxin ..mlstilrnnfvrrsfssrifsqneyetaadstlerlsdyfdqiadsfpvseqfdvshamgvltvnvsks
Mm_Frataxin ilnikkqsvcvvhlrnlgtldnpssldetayerlaeetldslaeffedladkpytledydvsfgdgvltiklggd
Hs_Frataxin iwnvkkqsvyLmnlrksgtlghpgsldettyerlaeetldslaeffedladkpytfedydvsfgsgvltvklggd
FA_Mutations S Y V
2D_Structure ..............AAAAAAAAAAAAAAAAAAA........BBBBBB...BBBBBB...
Frataxin_No. ....70........80........90.......100.......110.......120.......130.......14
    Ec_CyaY gskiiinrqeplhqvwlatkq-ggyhfdlkg--dewicdrsgetfwdlleqaatqqag-etvsfr*
    Yp_CyaY gskivinrqeplhqvwlatka-ggyhfnyrd--ghwycsrsgeeflaklseaasaqag-envsfg*
   Ech_CyaY gskivinrqepmhqvwlatkg-ggyhfdyqh--grwicdrsgsdfmallaqacteqsg-eeihfd*
    Hi_CyaY rtqivinkqepllelwiaskl-ggfhfafkn--gdwvs-ndgqrfwdcfveaca-ahg-envqf*
    Rp_CyaY -giyvintqsaskeiwlsspvsgphhffyeq--gkwks-rigfelmvllteelgirfd--kyeif*
At_Frataxin lgtyvlnkqtpnrqiwmsspvsgpsrfdwdrdanawiyrrteaklhklleeelenlcg-epiqls*
Sc_Frataxin fgtyvinkqppnkqiwlasplsgpnrfdlln--gewvslrngtkltdilteevekais-ksq*
Sp_Frataxin kgtyvinkqppahqiwlsspvsgpkhyeyslksktwcstrdegtllgilssefskwfs-rpiefkksedf*
Ce_Frataxin vgtyvinkqspnkqiwlsspmsgpkrydleee-gkwtyahdgeqldsllnrefrkiladdridfsrhv*
Mm_Frataxin lgtyvinkqtpnkqiwlsspssgpkrydwtg--knwvyshdgvslhellareltkaln-tkldlsslaysgkgt*
Hs_Frataxin lgtyvinkqtpnkqiwlsspssgpkrydwtg--knwvyshdgvslhellaaeltkalk-tkldlsslaysgkda*
FA_Mutations FRP C G HR
2D_Structure ..BBBBBB......BBBBB...bbBBBBBB. .BBBB...bbbAAAAAAAAAAAAA. ...............
Frataxin_No. 0.......150.......160.......170 .......180.......190..... ..200.......210
Structure
Figure 2
Superposition of the HSQC spectra of S_Fra and L_Fra. The spectra
were recorded at 600 MHz and 27°C.
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N
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N-terminal histidine tag and the last three C-terminal
residues, most of the fold is well defined in the bundle
with a root mean square deviation (rmsd) of 0.70 ± 0.12 Å
for the backbone atoms from residue 95–205. The loops
are relatively well structured with the exception of the
β6β7 loop (residues 176–179) which is less ordered, for
example as shown by the absence of nuclear Overhauser
enhancements (NOEs). Many loop residues, including
small hydrophilic residues (threonines and serines), and
glycines and prolines, are well conserved among the
frataxin family.
The seven-stranded antiparallel β sheet is solvent-
exposed on one side and packs tightly against the two
helices on the other (Figure 4b). The two helices lie
roughly parallel to each other and their orientation with
respect to the β sheet is unambiguously defined by
NOE data (e.g., between Tyr118 and Thr196, Thr102
and Leu182, Thr102 and His183). The C-terminal tail
spanning residues 194–206 fills a groove formed
between the two helices as supported by several NOEs
(e.g., Tyr205 forms a dense network of contacts with
distal residues). Despite the presence of a number of
sequential HN–HN connectivities, all the other NMR
observables exclude the presence of a helical conforma-
tion in this region. 
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Figure 3
NMR parameters related to the secondary structure of S_Fra. (a) Plot
of the secondary Cα chemical shifts versus the frataxin sequence. In
the top line, squares indicate slow-exchanging amide protons in
hydrogen-deuterium exchange experiments. In the second line,
diamonds and bars refer to 3JHNHA values typical of α-helical (3JHNHA
smaller than 5.5 Hz) and β sheet (3JHNHA larger than 8 Hz)
conformation, respectively. (b) The seven-stranded antiparallel β sheet
of frataxin. Continuous lines identify observed interstrand NOEs.
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Table 1
Relevant parameters that define the quality of the calculated
structures of S_Fra.
No. of restraints * † ‡
Total 951 2114 234
Intraresidue 328 1022 55
Sequential 326 399 25
Medium-range 112 236 43
Long-range 185 457 111
Angle restraints§ 0 42
Hydrogen bonds 50 50
Rmsd from ideality
Bonds Å 1.13E-3 ± 1.36E-4
Angles (°) 0.31 ± 1.06E-2
Impropers (°) 0.32 ± 0.06 
Energies (kcal/mol)
E total 143.78 ± 19.410
E bond 3.393 ± 0.783
E angle 56.450 ± 0.784
E vdW 67.228 ± 9.370
E NOE 12.701 ± 5.398 
E CDIH 0.024 ± 0.017 
Quality control
PROSA (kT)# –1.92 ± 0.09 
WHATIF¶ –1.009 ± 0.050
PROCHECK¥ 71.1 
Fit to experimental data** 
Unambiguous NOEs 9.942E-3 ± 2.368E-3 
Ambiguous NOEs 8.714E-3 ± 4.121E-3  
All NOEs  9.909E-3 ± 2.257E-3 
Hydrogen bonds 1.078E-2 ± 3.908E-3  
Dihedrals 8.109E-2 ± 3.587E-2 
Rmsd††
Backbone‡‡ 0.43 ± 0.07 
Heavy atoms‡‡ 0.98 ± 0.11   
Backbone (95–205) 0.70 ± 0.12 
Heavy atoms (95—205) 1.20 ± 0.15
*Distribution of the hard restraints used in DYANA. †Distribution of the
unambiguous restraints at the last ARIA iteration. ‡Distribution of the
ambiguous restraints at the last ARIA iteration. #Backbone dihedral
angle restraints were based on 3JHNHA coupling constants measured in
a 3D HNHA spectrum. For α helical regions (3JHNHA smaller than
5.5 Hz) dihedral angle values of φ = –60 (± 40) were used. For 
β strands (3JHNHA larger than 8 Hz) the values were taken as φ = –120
(± 40). #Calculated according to [44]. ¶Calculated according to [45].
¥Percentage of residues in most favourable regions of the
Ramachandran plot [43]. **Given in Å. ††Rmsd in Å are calculated from
the first best structure in terms of total energy. ‡‡Rmsd on the elements
of secondary structure 95–113, 122–127, 131–136, 142–147,
154–158, 162–169, 172–175 and 182–194.
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Structure similarity searches did not produce a significant
match with any other protein except for p32 (with an rmsd
of 3.2 Å over 56 residues and a Z score of 3.0), a mitochon-
drial matrix protein important for the maintenance of
oxidative phosphorylation [29]. Despite some similarities
in the fold and mitochondrial localization, however,
frataxin and p32 have very different contact patterns,
which implies no detectable evolutionary relatedness.
Sequence conservation can be mapped onto the structure
The frataxin C-terminal domain folds as a very compact
globular protein with no cavities or grooves. The helices,
together with the C-terminal tail, shield the hydrophobic
face of the β sheet. This must be crucial for the stability of
the fold as it allows formation of extensive interactions
between the hydrophobic residues that are conserved in the
frataxin family (Figure 5a). The hydrophobic core is domi-
nated by the presence of aromatic sidechains (11 residues).
One of the key residues is the conserved Trp173 (accessi-
ble surface area of 0.87 Å2) that is surrounded by Tyr95,
Trp168, Tyr205 (all well conserved). Together, they build a
very compact aromatic cluster around Leu98, of which the
sidechain points directly into the aromatic ring of Trp168 as
reflected from its δ-protons, which are ring-current shifted
to the most high field resonances of the spectrum (–0.18
and –0.6 ppm). A second aromatic cluster involves residues
located at the end of the first helix (Phe109, Phe110), which
have long-range contacts with residues in the first strand
(Tyr123) and the first loop (Tyr118). 
The conserved exposed residues all cluster on one side of
the protein, encompassing the solvent-exposed face of the
first helix and the β sheet (Figures 5b,c). Most of them
are, as expected, hydrophilic residues (Glu100, Glu108,
Glu111, Asp112, Asp122, Asp124, Thr133, Asn146,
Lys147, Gln148, Phe150, Gln153, Ser157, Arg165 and
His177) with the exception of Val131, Val144 and Trp155,
Val174. The negatively charged residues are aligned along
an edge formed by α1 and β2, producing a negatively
charged ridge (Figure 5d). Given that the protein is
monomeric in solution (see Materials and methods
section), conservation of exposed residues must be
explained by formation of a functional surface and there-
fore provide clues to the nature of the ligand. 
The frataxin structure has distinct features from iron-
binding proteins
In iron transporter proteins, which contain high affinity
iron-binding sites, iron is either chelated by a haem or
forms an iron–sulphur cluster or, as in transferrin, binds to
a cluster of glutamate, histidine and tyrosine residues that
sit in a pocket formed between two globular subunits. A
strikingly similar di-iron binding centre is found in ribonu-
cleotide reductase, methane monoxygenase hydroxylate,
haemerythrin and ferritin (for a review see [30]). The di-
iron centres of these proteins are all hidden in a
hydrophilic cavity buried in a four-helix bundle. The
frataxin structure does not have any pockets or cavities
able to accommodate a haem in the C-terminal domain
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Figure 4
C
N
C
N N
C
Structure
(a) (b)
Tertiary structure of  S_Fra. (a) NMR bundle (residues 91–210 of the human frataxin sequence). Stereo pair of a backbone bundle of the 15 best
calculated structures. The fitting was obtained by superimposing the backbone atoms of residues 95–205 onto the average structure. (b) Ribbon
representation of S_Fra with helices in red and strands in blue.
st8705.qxd  07/03/2000  09:33  Page 699
(Figure 4). The additional 15 amino acids present in the
mature form of frataxin are not conserved among species
and, even assuming species diversity, do not contain
residues that could help to fix the haem to the structure.
700 Structure 2000, Vol 8 No 7
Figure 5
Mapping residue conservation to the structure
of S_Fra. (a) Ribbon representation of S_Fra
showing the conserved and hydrophobic
sidechains (in green) implicated in packing of
secondary structure elements. (b) Surface
distribution of phylogenetically conserved and
exposed amino acids. CPK representation of
the asymmetric distribution of the exposed
conserved residues (in cyan hydrophilic
sidechains, in green hydrophobic sidechains).
(c) View of the same representation after 180°
rotation around the y axis. (d) Charge
distribution on the protein surface as viewed
from the same direction as in Figure 5b.
Positively and negatively charged electrostatic
potentials are indicated in blue and red,
respectively. The surface was calculated by
using a probe radius of 1.4 Å, and the potential
displayed at the scale of –14 kbT to +14 kbT,
where kb is the Boltzmann constant. A
significantly high number of negatively charged
residues is present on the first helix.
(e) Charge distribution on the opposite side of
the protein (same orientation as in Figure 5c).
180º
D122
D124
D112
E111
E108
W155
E100
N146
V131
V144
K 147 Q148
R165
H177
T133
R165
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Cysteines are rare in the frataxin family and the few that
are present are not conserved. 
Although ferritin-like properties have been proposed for
frataxin [26], comparison of the structures shows some
weak similarities and a number of important differences.
The negatively charged ridge along α1 could be imagined
to provide an ion-binding site but, in contrast to that
observed for most ferritins, it would be highly exposed
and would require more than one protein molecule for its
formation. An exposed ferroxidase centre has been
described recently, however, for Listeria innocua ferritin,
the only example of a ferritin in which iron is chelated by
two different subunits [31]. Apoferritins spontaneously
assemble into large aggregates (of 24 or 12 subunits) in the
absence of iron [30] whereas frataxin has no tendency to
self-aggregate, even at the millimolar concentrations that
are used for NMR. Overall, the surface of frataxin is much
less charged than that of ferritin. The hollow core of fer-
ritin 24-mers is lined with negative charges that interact
with the enclosed inorganic iron precipitate. The frataxin
surface conservation is highly asymmetric; one side only of
the molecule is conserved, with the negative ridge
forming a border between conserved and unconserved
residues (Figure 5). This configuration does not seem suit-
able for the formation of an analogous ferritin-like aggre-
gate with negative charges pointing into the centre.
Finally, the presence in frataxin of an exposed surface
including absolutely conserved hydrophobic residues such
as Trp155 strongly suggests a partner other than iron. 
Is frataxin an iron-binding protein?
Different approaches were used to study the potential
binding properties of frataxin to iron. In order to check the
presence of site-specific conformational changes at high-
affinity binding sites such as those observed in
monomeric/dimeric iron-transporter proteins (e.g., ferro-
doxin, transferrin) NMR was used. L_Fra that corresponds
to the mature form of frataxin was titrated with Fe2+ and
Fe3+ up to a protein/iron ratio of 1:3. On addition of iron
ions of either oxidative state, no chemical shift changes
were observed in the HSQC spectra (Figure 6a). Given
that neither the linewidths nor the intensities of the reso-
nances showed any variation, formation of large aggregates
and/or precipitation and removal of signals by paramag-
netic ion line broadening can be excluded. These in vitro
data show conclusively that monomeric frataxin does not
have a high-affinity iron-binding site. 
To further check whether or not an excess of iron could
promote aggregation similar to what is observed for ferritin,
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Iron binding assays. 15N-edited HSQC spectra recorded at 500 MHz
and 27°C of L_Fra using a 0.4 mM solution sample at pH 7.2.
(a) Spectrum of the protein alone and (b) spectrum of the protein with
an excess of Fe2+ ([frataxin]:[Fe2+]1:3). (c) Elution profile of L_Fra after
the addition of ferrous ammonium sulphate in a protein:iron ratio of
1:40 loaded on a high load 10/30 Superdex column. The scale on the
vertical axis is in milli-absorption units (mAU). The same profile was
invariably observed for all the different protein:iron ratios tested.
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L_Fra was titrated with an iron excess (up to a ratio of
1:1000) and the solution applied either on a native gel or on
an analytical gel-filtration column. In both cases, however,
no aggregation was observed (Figure 6b). 
All the clinically important mutations occur at conserved
sites of the frataxin structure
Given that the GAA expansion alters protein levels, but
the FRDA point mutations directly affect function of the
expressed protein, examination of the point mutations in
the FRDA gene might be useful to gain new insights
into the role of frataxin in the ataxia. The currently
known missense mutations are restricted to the C-termi-
nal domain of frataxin. The mutations can thus be
mapped on the structure and their effects rationalised
according to their location (summarised in Table 2).
Seven mutations occur in positions occupied by
hydrophobic residues conserved in the frataxin family
and are either involved in the protein core or important
for the conformation of loop regions (Figure 7a). These
mutations might be expected to have deleterious conse-
quences on the fold stability. Three mutations
(Asp122→Tyr, Trp155→Arg and Arg165→Cys) occur at
surface sites and all affect strongly conserved residues
(Figures 7a,b). 
Two representative FRDA point mutations (Ile154→Phe,
Trp155→Arg) were chosen for expression in
Escherichia coli. The first is one of the most common muta-
tions, described in several independent families [9], and
leads to a severe phenotype. The second was chosen
because the mutation involves an exposed, but absolutely
conserved tryptophan [32]. The mutations were intro-
duced into the L_Fra construct. As compared with the
wild-type, the expression yields of the two mutants were
both low with part of the protein forming inclusion bodies,
suggestive of a difficulty in adopting a native conforma-
tion. In both cases, however, protein could be purified
from the soluble fraction. The fold and the stability of the
purified soluble fraction of both mutants were compared
with those of the wild-type using CD spectroscopy. At
room temperature, the far-UV CD spectra of the three
proteins have similar features, indicating that the fold is
retained in the mutants (data not shown). The wild-type
melting temperature, as followed by CD thermal denatu-
ration curves, was found to be 62°C. The two mutants are
clearly less stable than the wild-type and the melting
points are 12°C lower for Ile154→Phe and 7°C lower for
Trp155→Arg (Figure 7c). Of the two mutants, only the
refolding of the Trp155→Arg mutant is reversible under
the conditions used in vitro. 
Discussion
Frataxin seems to be an important protein present in all
species and is essential for survival [8,11]. We have shown
here that the mature protein forms two structurally dis-
tinct regions of which only the evolutionary conserved
C terminus is folded and forms a compact globular
domain. Even if folded, the remaining 15 residues present
in the mature form of frataxin do not influence the stabil-
ity of the C terminus, therefore suggesting that they do
not interact with it. Although the biochemical function of
frataxin remains unclear, the structure provides the first
guidelines to the nature of the ligand and allows us to
rationalise a number of observations that could not be
explained by the primary structure of the protein alone. 
From the tertiary fold, we can distinguish residues that are
buried inside the fold and are important for its stability
from those that are exposed and yet conserved through
evolution. Residues on the surface are probably conserved
for functional reasons and therefore can be suggestive of
interaction sites with potential frataxin ligands. Residues
that are exposed but conserved in the whole frataxin
family cluster only on one face of the structure, the one
containing the β sheet and the edge of α1. The conserva-
tion covers a span of approximately 30 Å and an area of
more than 1400 Å2, a region larger than would be expected
for a small molecule as a single ligand. This suggests
either that two or more ligands are brought together, or
that a single partner, for example another protein or a
nucleic acid molecule, is involved. In either case, the
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Table 2
Summary of the mutations described in FRDA patients.
Mutation Effect References 
Lys106→Ser, Trp173→Gly Internal cavities with [47]
loss of packing energy [9]
Ile154→Phe, Leu182→Phe Steric strain by replacing a buried [8]
hydrophobic residue by a larger one [48]
Leu156→Phe Disruption in the β-sheet hydrogen [9]
bonds by introducing a proline
Gly130→Val Steric strain by replacing a glycine [49]
which is in a conformation that is not
allowed for other residues
Leu182→His Electrostatic strain by replacing a [9]
buried residue with a hydrophilic one
His183→Arg Electrostatic strain by replacing a [9]
partially uncharged buried residue
with a bulky charged one
Asp122→Tyr Change of identity of a conserved [9]
negatively charged group on the
surface
Trp155→Arg Replacement of a bulky highly [33]
conserved aromatic sidechain
with a positively charged residue
Arg165→Cys Replacement of a conserved [50]
positively charged group with
an exposed cysteine that might
form intermolecular disulphide bridges
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ligand(s) will have to match a large composite surface and
complement the pattern of conservation formed by the
negative ridge composed of Glu108, Glu111 and Asp124,
by the central hydrophobic patch and the conserved posi-
tive groups of Arg165 and His177 (Figure 5b). 
Mapping the pathological mutations onto the structure is
the basis for rational design of experiments to test the role
of individual residues of frataxin in ligand recognition and
for understanding the effect of mutations that cause the
disease. Interestingly, all missense mutations observed so
far map in the evolutionary conserved frataxin C terminus
encoded by exons 4 and 5a (Figures 1 and 7). This observa-
tion strongly supports the hypothesis that the C terminus is
the functionally most relevant region of the protein. The
two mutants that were tested are both folded at room tem-
perature but show distinct features from the wild-type.
The Ile154→Phe mutation has greatly reduced thermody-
namic stability and poor refolding ability. These effects
could lead to much reduced levels of functional frataxin in
the cell, either because of refolding difficulty after import
into the mitochondria, or because of a more rapid turnover
of poorly stable mature frataxin. A lower refolding effi-
ciency would also agree with the slower maturation pro-
cessing observed by H Koutnikova and colleagues [25]
(but not validated by Gordon et al. [27]). The Trp155→Arg
mutation is even more interesting. Because of the conser-
vation of the tryptophan on the protein surface, the effect
of the Trp155→Arg mutation should not only interfere
with the refolding pathway (although to a lesser extent
than the Ile154→Phe mutant) but also disrupt the ligand-
binding site. Such expectation makes this mutation an
excellent candidate for the design of in vivo knockouts in
model organisms and to test ligands in vitro. 
Molecular research into FRDA has burgeoned since the
gene responsible was cloned [8]. Previously, almost
nothing was known about the underlying biochemical
defect. It is now well-established that the disease results
from oxidative damage associated with iron accumulation
in mitochondria and experimental antioxidant therapies are
being evaluated [23]. The prevailing hypothesis supposes
that frataxin is involved in the regulation of mitochondrial
iron import/export, although it has been unclear how direct
this might be. There has been some expectation that
frataxin would itself prove to be an iron-binding protein.
The presence of conserved negatively charged residues in
the sequence, which cluster together on the same surface
of the structure, suggests a binding site for positive ions.
However, experimentally we do not observe any high-
affinity iron-binding site. Furthermore, whereas all of the
known high-affinity iron-binding sites are formed by con-
served pockets formed in the interior of the protein
monomer, no pocket is observed in the frataxin structure.
On the other hand the recent report that yeast frataxin has
ferritin-like iron storage properties and is able to form
large aggregates that sequester iron from solution is a very
interesting possibility [24]. Ferritin has features very dis-
tinct from those of iron-transporters as it forms large
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Characterization of clinically occurring mutations. (a) Mapping on the
S_Fra structure of the known point mutations occurring in Friedreich’s
ataxia patients: the sidechains of the amino acids corresponding to the
point mutations are shown in green (hydrophobic residues) and cyan
(hydrophilic residues). The view is the same as in Figures 5b,d.
(b) Space-filling representation of the surface of frataxin in the same
orientation as in 7a. (c) Thermal denaturation curves monitored by far-
UV circular dichromism. The melting curves were followed by
recording the signal of the spectrum of L_Fra at 223 nm (dashed line),
the Trp155→Arg mutant (dashed-dotted line) and the Ile154→Phe
mutant (dotted line).
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aggregates of 24 subunits. The polymer forms a large
hollow cavity in which up to 4500 Fe3+ molecules can be
stored as an inorganic complex. In frataxin, the conserved
exposed hydrophobic residues could be part of a self-
aggregation surface whereas the negatively charged ridge
could be the equivalent of the ferroxidase ferritin centre
reminiscent of that observed for Listeria innocua ferritin
[31]. The fine details (the monodisperse behaviour of
mature frataxin, the lack of a buried hydrophilic site, a
much less charged exposed surface, the nature of the con-
served hydrophobic residues) suggest that, if frataxin had
iron storage properties, its assembly behaviour and iron
storage would have a very different mechanism from that
of ferritin. Experimentally, we were not able to reproduce
the experiments described for yeast frataxin [24], which
suggests that the two proteins could have a different
in vitro behaviour. On the other hand it is true that,
because a ferritin-like behaviour has been observed
in vitro without having relevance in vivo [33,34], more
work at the cellular level might be necessary to prove iron
storage properties for frataxin.
An indirect involvement of frataxin in iron homeostasis
cannot, therefore, be ruled out. Iron accumulation as a sec-
ondary effect of another misfunction is observed in other
diseases: the X-linked childhood sideroblastic anaemia
and ataxia (XLSA/A: OMIM 301310) is caused by a partial
loss-of-function mutation in the ABC7 gene, which medi-
ates export of iron–sulphur (Fe–S) cluster precursors [35].
An indirect involvement of frataxin in iron metabolism
would also agree with the recent report of the knockout of
the E. coli cyaY, a gene conserved in all the purple bacter-
ial species so far examined [11,36]. Although cyaY is the
orthologue of eukaryotic frataxin and shares with it a
common conserved exposed pattern (Figures 1 and 5b),
the E. coli knockout shows neither an effect on the cellular
iron content nor sensitivity to oxidants [36]. Although it is
tempting to argue that as we could find no clear differ-
ences in the pattern of conserved residues, the biochemi-
cal functions of cyaY and frataxin have diverged, the
sequences provide no grounds for making this assertion;
that is despite the dramatic differences in phenotype, the
precise biochemical functions of cyaY and frataxin could
ultimately prove to be identical.
There are a number of ways in which frataxin might indi-
rectly fit into the iron regulation system. Frataxin could
function as a carrier of an antioxidant (such as vitamin E or
glutathione). If its partner is a protein (which cannot be
excluded because failure of the two-hybrid screen experi-
ments attempted so far could be simply because of various
technical reasons), it is tempting to suggest an interaction
with one of the Fe–S proteins of a respiratory complex.
Fe–S cluster proteins in respiratory complexes I, II and III,
together with aconitase have indeed been found to be defi-
cient in FRDA [20]. Atm1 (the yeast ABC7 orthologue) has
also been proposed to be regulated by the frataxin homo-
logues [37]. Frataxin could be involved in protein import
and processing, perhaps as a chaperone or adaptor.
Biological implications
Friedreich’s ataxia (FRDA) is a recessive neurodegen-
erative disorder that involves progressive physical dis-
ability, dysarthria, muscular weakness, and can lead to
premature death due to hypertrophic cardiomyopathy
[2,3]. The locus for FRDA was recently mapped to a
single gene located in chromosome 9 and encodes a
small mitochondrial protein of 210 amino acids named
frataxin [8–10]. The protein is essential for life and is
present in living organisms ranging from purple bacteria
to humans [11]. Reduction of the frataxin concentration
in mitochondria leads to disregulation of iron homeosta-
sis, with concomitant oxidative damage leading to neu-
ronal death [12,14–20]. An important point that has
been questioned is, therefore, whether or not frataxin is
an iron-binding protein. Structural characterization of
recombinant frataxin shows that the mature protein is
composed by an N-terminal tail and an independently
folded C-terminal domain with an α–β globular fold.
The structure of the protein does not share any of the
features typical for iron-binding proteins, strongly sug-
gesting that the involvement of frataxin in iron metabo-
lism is indirect. Iron-binding could also not be supported
experimentally. Mapping of sequence conservation onto
its surface suggests a large surface of interaction, which
selectively clusters on one face. Although the specific
partner (or partners) of frataxin remain for the moment
only speculative, the speed of progress made in the past
few years not only in experimental treatment but also in
a deeper comprehension of the metabolic bases of the
disease holds a realistic hope that FRDA might soon be
a treatable condition. In this perspective, the establish-
ment of the frataxin structure and of an interaction
surface discussed in the present work, together with
rationalization of the effect of clinically occurring muta-
tions, will provide useful guidelines for future biochemi-
cal and clinical experimentation.
Materials and methods
Sequence analysis
New frataxin homologues were retrieved by using an alignment of the
C-terminal domain for profile searches on the Bioccellerator
(http://shag.embl-heidelberg.de:8000/). Accession numbers of
sequence entries in SWISS-PROT or SPTREMBL are: Q16595,
Human FRDA (Hs in Figure 1); O35943, Mus musculus FRDA (Mm);
AAC71159, Caenorhabditis elegans FRDA (Ce); O74831, Schizosac-
charomyces pombe FRDA (Sp); Q07540, Saccharomyces cerevisiae
FRDA (Sc); Q9ZR07, Arabidopsis thaliana FRDA (At); P27838, E. coli
cyaY (Ec); P71358, Haemophilus influenzae cyaY (Hi); P46356,
Yersinia pestis cyaY (Yp); P40128, Erwinia chrysanthemi cyaY (Ech);
Q9ZDK5, Rickettsia prowazekii cyaY (Rp).
Protein expression and purification
The two C-terminal L_Fra and S_Fra fragments of human frataxin
(residues 63–210 and 91–210 respectively; accession number
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U43752) were amplified using the polymerase chain reaction (PCR).
The S_Fra construct was expressed with a His-tag of ten additional
residues at the N terminus (MKHHHHHHPM) included for purification
purposes and not removed. (Met10 substitutes for the semiconserved
residue Leu90). L_Fra was obtained by cloning it into a pET9-derived
plasmid vector behind the encoded His-tag and glutathione-S-trans-
ferase (GST). The Ile154→Arg and Trp155→Arg mutants were
derived, also as GST-fusion proteins, from L_Fra using a site-directed
mutagenesis kit (Quiagen). The constructs were expressed in E. coli
strain BL21 (DE3) transformed with a modified pET vector DNA. For
protein expression, the cells were inoculated into 4 l luria broth medium
with ampicillin (100 mg/l, for the short construct) or kanamycin
(30 mg/l, for the long construct and the mutants), induced for 3–4 h by
addition of 0.2 mM isopropyl β-D-thiogalacto-pyranoside (IPTG) after
the cultures reached an optical density (OD) between 0.6–0.8 at
600 nm. The cell pellets were harvested and frozen. The frozen cells
were thawed in a lysis buffer and subsequently sonicated and cen-
trifuged. Ni-NTA chromatography was applied as a first step of purifica-
tion both to the His-tagged S_Fra and to the GST-fused constructs
(L_Fra and mutants). The soluble over-expressed proteins were passed
through a nickel column and eluted with imidazole (pH 8.0).
Fra was further purified over a MonoQ column (Pharmacia). The
peptide (with an isoelectric point of 5.82) was eluted at about 0.3 M
NaCl and concentrated by ultrafiltration. Final purification was achieved
by gel filtration chromatography on a Superose-12 column (Pharmacia)
equilibrated in 40 mM potassium phosphate pH 7. The frataxin peptide
eluted in the retention volume predicted for a monomeric 14.7 kDa
protein. L_Fra and its mutants were dialyzed against 20 mM Tris-HCl
buffer with 100 mM NaCl pH 8, concentrated with Amicon concentra-
tor (model 8050) and loaded on a Superdex 16/60 high load gel-filtra-
tion column equilibrated with 20 mM Tris-HCl, 500 mM NaCl at pH 8.
The fractions containing the pure proteins were pooled together and
concentrated. The purity of the recombinant proteins was controlled by
SDS–PAGE after each step of the purification and by mass spec-
troscopy on the final products.
15N-labelled samples were produced by growing the bacteria in
minimal medium using (15NH4)2SO4 as sole source of nitrogen, and
doubly labelled samples were produced using (15NH4)2SO4 and
13C6-D-glucose.
Analytical gel filtration was used to check whether L_Fra is mono-dis-
perse in solution. Ovalbumin (43 kDa), chymotrypsinogen A (25 kDa)
and ribonuclease A (13.7 kDa) were used as molecular standards for
the mass calibration curve. The molecular weight of a 25 µM solution of
L_Fra is consistent with that expected for a monomeric species.
Structure calculations
Spectral assignment was performed as described in [28]. In order to
reduce ambiguities in the assignment of the aromatic sidechains, 3D
Constant Time [1H/13C]-TROSY CCH-COSY [38], 2D CT-Cγ(CC)H
(mixing time 4.2 ms and 13.6 ms), and 2D CT-Cγ(Cβ)Hβ [39] were
performed on a BRUKER 800 MHz DRX spectrometer. Deuterium
exchange studies were performed on a lyophilised sample of 15N-
labelled protein redissolved in deuterated phosphate buffer (pH 6.8).
Six 15N HSQC spectra were collected at 25°C on a BRUKER DMX
over a period of 24 h. Amide protons were considered to exchange
slowly if they were still visible in the spectrum recorded 24 h after
adding D2O. Interproton distance restraints were derived from three
heteronuclear 3D-NOESY spectra at 27°C with mixing time of 100 ms
(NOESY-15N-HSQC, NOESY-13C-HSQC and NOESY-13C-HSQC
optimised for aromatic residues). 
Structure calculations were performed using the programs DYANA
(version 1.5) [40] and ARIA interfaced with CNS-0.5 [41]
(http://www.NMR.EMBL-Heidelberg.DE/nmr/nilges/). Preliminary DYANA
runs were performed to clear the data from possible mistakes and incon-
sistencies. For these runs, coupling constants, hydrogen bonds and up to
951 manually assigned upper distance constraints, autocalibrated with
the DYANA associated module CALIBA, were progressively incorpo-
rated. In the final DYANA run, 60 random conformers were annealed in
10,000 torsion angle dynamics steps using the standard annealing proto-
col. The average residual target function for the ten best conformers was
3.85 ± 0.67 Å2, the mean global backbone rmsd and heavy atom rmsd
(on the secondary structure elements) was 3.60 ± –0.67 and
4.44 ± 0.67 Å, respectively). The structures had a low convergence, as
expected from the relative small number of constraints used in the calcu-
lation. However, this result was sufficient to get a preliminary picture of
the fold of the protein.
To confirm the fold and automatically to increase the number of NOE-
derived restraints, the refined structures were calculated by ARIA. For a
typical ARIA run, consisting of eight iterations, a total of 20 structures
per iteration were calculated. In each ARIA iteration, structures were cal-
culated with a CNS simulated annealing protocol with 10,000 initial MD
steps, 2000 MD steps in the high-temperature stage at 2000K, 5000
steps in the first cooling stage from 2000K to 1000K, and 2000 steps
in the second cooling stage from 1000K to 50K. The time step was
0.005 ps. Floating assignment for prochiral groups was applied as
described in [42]. In the first iteration, initial structures were calculated
on the basis of the manually assigned XEASY peak lists, 42 hydrogen
bonds and 50 φ dihedral angles. In the following iterations, the remain-
ing NOEs were automatically calibrated and assigned by the ARIA sub-
routines. The seven best structures resulting from each run were
selected and used to extract additional NOE restraints from the peak
lists. These raw data were converted into distance restraints based on
the assigned chemical shifts with a tolerance of 0.5 ppm on the het-
eroatom dimension, of 0.04 ppm on the direct dimension and of
0.03 ppm in the indirect dimension. The three peak lists were inspected
with respect to the seven lowest energy structures from the previous
iteration. A restraint was not used if it was violated by more than a target
value in maximally 50% of the seven structures. The target value was
gradually tightened using a violation tolerance (violtol) from 5 to 0.0 Å,
the assignment parameter (ambigcutoff) was varied from 1.01 to 0.80.
With the decreasing level of ambiguity in the ARIA/CNS iterative proce-
dure, more restraints could be assigned unambiguously resulting in a
rapid convergence of the structure. The total number of unambiguous
and ambiguous NOE restraints after ARIA refinement was 2114 and
234, respectively. In the last iteration, 50 structures were generated by
ARIA and the 15 having the lowest energy were used for statistical
analysis. None of these structures exhibits distance violations greater
than 0.5 Å or dihedral angle violations greater than 5°.
Structure analysis
The Ramachandran plot was analyzed with PROCHECK-NMR (version
3.4) [43]. Additional quality controls were performed with the programs
PROSA [44] and WHATIF [45]. Secondary structure elements and
Rmsd values were calculated using MOLMOL (version 2.6). Structure
and folding similarity searches in the PDB were performed using DALI
(http://www2.ebi.ac.uk/dali/).
Iron binding assays
15N-labelled L_Fra was used for iron titration. To avoid any other metal
contamination, an excess of EDTA (frataxin:EDTA 1:4) was added to
the sample and then removed by gel filtration on a PD-10 column
(Pharmacia). In order to solubilize the iron ions, Fe(NH4)2(SO4)2⋅6H2O
and FeCl3 were dissolved in 20 mM citrate, which was used as iron
carrier. For each of the titration experiments, 500 µl of 0.4 mM frataxin,
10 mM Tris (nondeuterated), 10 mM NaCl, pH 7.2 (90% H2O and
10% D2O) were prepared in a 5 mm NMR tube. In order to keep dilu-
tion and NMR signal loss at minimum, titrations with both Fe2+ and
Fe3+ were carried out by adding microliter amounts of concentrated ion
stock solutions of 10 mM (pH 8.2) to the NMR samples, up to a stoi-
chiometric ratio of frataxin:iron of 1:3. Concentrations of the protein
were derived by UV using an extinction coefficient of 26030 M–1cm–1
at 280 nm. For each titration point, a two-dimensional 15N-edited
HSQC spectrum was recorded at 27°C.
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A screening to check conditions that could promote aggregation of
frataxin in the presence of iron was achieved by native gel and gel filtra-
tion. Increasing quantities of ferrous ammonium sulphate (SIGMA) were
added to a solution of protein (protein concentrations used were either
8 or 25 µM) to reach protein:iron ratios between 1:20 and 1:1000.
Three sets of titrations were performed, one at pH 7 in 100 mM HEPES
and incubated overnight at 30°C. Two more titrations were performed at
lower pH (pH 6 in 100 mM MES) and incubated for 60 min at room tem-
perature and 4°C, respectively. These conditions were chosen to slow
down Fe(II)/Fe(III) oxidation and allow interaction with the protein if this
interacted with Fe(II) only. The iron precipitate was centrifuged and the
supernatant loaded on a 6% polyacylamide native gel. In all cases, the
protein was visible in the gel and ran as a monomer. The same proce-
dure was repeated and the supernatants analyzed by gel filtration using
a high load column 10/30 Superdex equilibrated with the corresponding
buffer, 300 mM NaCl at a flow rate of 0.5 ml/min. 
CD measurements
CD measurements were performed on a Jasco J-715 spectropolarime-
ter equipped with a thermostatically controlled cell holder stabilized by
circulating water from a Neslab RTE-111 water bath. A rectangular
quartz cuvette with 0.1 cm pathlength was used (Hellma). All the
spectra were baseline corrected by subtracting buffer spectra and the
observed ellipticity was then converted to mean residue weight elliptic-
ity [θ]/(degree*cm*dmol–1). CD spectra were averaged over five scans
obtained by collecting data at 0.5 nm intervals from 259–190 nm. A
rectangular quartz cuvette of 1 cm pathlength was used. All the experi-
ments were carried out in 20 mM Tris-HCl buffer at pH 8 using a
protein concentration of 9 µM. The thermal denaturation of the wild-
type and mutant frataxins were followed by monitoring the ellipticity at
223 nm from 16°C to 80°C. 
Accession numbers
The coordinates have been deposited in the Protein Data Bank with the
accession code 1DLX.
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